Since CV outcomes occur irrespective of glycemic control, patients and providers should be encouraged to continue well-tolerated, guideline-recommended GLP-1 RA therapy even when glycemic benefits are not as evident
Dos and Donts Dos : Talk to Your Doctor If youre pregnant or planning to become pregnant, discuss stopping GLP-1 medications with your healthcare provider
Whats missing is strong, long-term evidence that long-term microdosing produces comparable outcomes in weight, blood glucose control, and reduction of cardiovascular risk
July 2, got a text from CVS saying my Rx was ready with a copay of $50
Maybe it showed up between two other things on Instagram, maybe a friend mentioned the no-needle option, maybe you were searching "GLP-1 without insurance" at midnight
The SURPASS-3 study was started to study the efficacy and safety of TZP versus basal insulin degludec in diabetic patients inadequately controlled by metformin with or without an SGLT2-i for 52 weeks (7274)
